$LH

Schechter Adam H sold $1.5M of LH

Schechter Adam H (President & CEO) sold 4,669 shares of LABCORP HOLDINGS INC. (LH) at $320.37 ($1.50M total) on 2026-08-11 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · Schechter Adam H
Published Aug 12, 2026, 6:31 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Aug 12, 2026, 6:32 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$LH
Neutral
high confidence
Mentioned
$LH
Relevance
5/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$LHNeutralLow
01

Why it matters

The newest fact is the specific open-market sale details (shares, price, total value) and that it was executed under a pre-arranged Rule 10b5-1 plan.

02

Market read

Traders may monitor insider activity for sentiment, but this filing alone does not provide new operational or financial information.

03

What to watch

The disclosure does not state motives beyond the pre-arranged plan, and the sale size may be routine relative to holdings.

Relevance 5/10Novelty 3/10Timing: filed 2026-08-12, transaction dated 2026-08-11

Background

The article is an SEC Form 4 insider transaction filing for Labcorp Holdings (LH) by its President and CEO, Adam H. Schechter.

Company-level read

Ticker impact

$LHNeutralHigh confidence
Context

SEC Form 4 shows LH CEO Schechter sold 4,669 shares in an open-market transaction on 2026-08-11 under a 10b5-1 plan.

Expected impact

Low likelihood of a sustained price move; any reaction is likely muted and short-lived.

Evidence & confidence

The filing is a routine Form 4 with a stated 10b5-1 pre-arranged plan and no accompanying guidance, deal, or regulatory action.

Market effects

No sector-level signal; insider sale does not imply industry-wide change.

None indicated.

None indicated.

Counterpoint

Even with a 10b5-1 plan, repeated insider selling can be interpreted as confidence erosion by some traders.

Key entities

  • LH

    Labcorp Holdings Inc., the company whose insider transaction is disclosed.

  • Schechter Adam H

    President and CEO of LH, reporting an open-market sale under a 10b5-1 plan.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$LHMed

Why Labcorp Holdings Stock Dropped Today

Labcorp Holdings (LH) stock fell 3.3% after CMS announced plans to cut lab reimbursement rates by up to 15% starting in 2027. CMS payments accounted for 8% of Labcorp's 2025 revenue, according to its SEC filing. The company warned that reduced rates could materially impact its revenue and profitability.

$BABAMed

Stocks making the biggest moves premarket: Alibaba, Quest Diagnostics, On Holding, GameStop & more

Alibaba shares rose 3% after its CEO announced plans for 20+ gigawatts of data centers by 2032 and launched a new chip. Quest Diagnostics and Labcorp fell 5% each due to Medicare payment adjustments. Vicor gained 9% on strong Q3 guidance. On Holding jumped 6% after setting new financial targets and a $1B share buyback plan. GameStop rose 3.5% after its CEO bought 1.2M shares.

$DGXMed

Premarket movers: Quest, Labcorp hit by CMS cuts

U.S. stock index futures steadied on Tuesday. Quest Diagnostics (DGX) fell 6.9% and Labcorp (LH) dropped 4.5% after CMS proposed cuts to lab reimbursements. On Holding (ONON) rose 6.4% on a $1B share buyback plan. Vicor (VICR) surged 9.9% after raising Q3 revenue outlook. Endava (DAVA) fell 12% due to CFO investigation. GameStop (GME) gained 3.5% after CEO bought shares. AnaptysBio (ANAB) rose 3.8% on better-than-expected revenue.

$LHMedAI 8/10

Why is Labcorp stock sliding today?

Labcorp (LH) stock fell 3.4% after-hours to $310 following CMS's proposal to cut Medicare lab reimbursements by up to 15% annually starting 2027. CMS claims this corrects overpayments, potentially saving $1B yearly. Truist raised its price target to $365 but kept a Buy rating. Quest Diagnostics faces similar headwinds. The selloff was sector-specific, with broader markets flat.